News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PharmaGap Inc. (GAP) Announces Testing Program for Novel Cancer Drug Compound at the Ottawa Health Research Institute


3/24/2009 11:21:44 AM

OTTAWA, March 24 /CNW Telbec/ - PharmaGap Inc. (TSX-V: GAP - News; "PharmaGap" or "the Company") and the Ottawa Health Research Institute ("OHRI") have entered into a testing program for PharmaGap's lead cancer drug compound, PhG-alpha-1. OHRI researchers led by Dr. Barbara Vanderhyden will study the compound in ovarian cancer cell lines in order to assess the potency of PharmaGap's drug compound as a single agent therapeutic and in combination with the current standard of care chemotherapeutic used to treat ovarian cancer.

Read at Canada NewsWire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES